 
 
 
A Pi[INVESTIGATOR_723547] -Transplant Risk Stratification and Prophylactic Defibrotide to Prevent 
Serious Thrombotic Microangiopathy in High -Risk Hematopoietic Stem Cell Transplant Patients  
 
 
 
 
[STUDY_ID_REMOVED]  
 
 
 
 
IRB Last Approval Date: 8/ 4/[ADDRESS_988013] approval and informed consent, or as required by 
[CONTACT_14171].  Per sons to whom this information is disclosed should be informed that this information is 
privileged and confidential and that it should not be further disclosed.  A Pi[INVESTIGATOR_723547] -Transplant Risk Stratification and Prophylactic Defibrotide to 
Prevent Serious Thrombotic Microangiopathy  in High -Risk Hematopoietic  Stem  Cell 
Transplant Patients  
 
Protocol Number:  #      
Study Drug:  Defibrotide ( Jazz Pharmaceuticals)  
Version Number:  1.3 
Version Date:  9/18/2018  
IND Number:        
Principal Investigator (Sponsor -Investigator)  
Christine Higham , MD   
University of [LOCATION_004] San Francisco  
[ADDRESS_988014], 4th floor 
  San Francisco, CA 94 143 
Telephone:  415 -476-2188  
Fax:  415 -502-4867  
E-mail:   [EMAIL_13848]  
Co-Investigators  
Jasmeen Dara, MD  
Chris Dvorak, MD  
Craig Forester, MD  
James Huang, MD    
Sandhya Kha rbanda, MD  
 Alexis Melton, MD  
Kristin Shimano, MD  
Jennifer Willert, MD  
 
Clinical Research Coordinator  
Kevin Magruder    
University of [LOCATION_004] San Francisco  
[ADDRESS_988015], 4th floor 
  San Francisco, CA 94 143 
Teleph one:  415 -476-2188  
Fax:  415 -502-4867  
Revision History  
 Version 1.0  8/1/2017    
 Version 1.1 9/5/2017  
 Version 1.2  
 Version 1.3  2/27/2018  
9/18/2018  
   
 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 1 of 37 Protocol Signature [CONTACT_164309]. :       Version Date:        
1. I agree to follow this protocol version as approved by [CONTACT_723558] ( CHR )  
2. I will conduct the study in accordance with applicable CHR  requirements, Federal 
regulations, and state and local la ws to maintain the protection of the rights and welfare of 
study participants.  
3. I certify that I, and the study staff, have received the requisite training to conduct this 
research protocol.  
4. I have read and understand the information in the Investigators’  Brochure (or Manufacturer’s 
Brochure) regarding the risks and potential benefits. I agree to conduct the protocol in 
accordance with Good Clinical Practices (ICH -GCP), the applicable ethical principles, the 
Statement of Investigator (Form FDA 1572), and w ith local regulatory requirements. In 
accordance with the FDA Modernization Act, I will ensure the registration of the trial on the 
www.clinicaltrials.gov website.  
5. I agree to maintain adequate and accurate records in accordance with CHR  policies, 
Federal,  state and local laws and regulations.  
UCSF Principal Investigator  / Study Chair    
Printed Name    
[CONTACT_633756](s)  
        
        
        
Telephone:        
E-mail:                
        
        
Telephone:         
E-mail:                
        
        
Telephone:        
E-mail:        
 
Principal Investigator   [INVESTIGATOR_723548]:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page [ADDRESS_988016] of care.  
Duration of 
study  The study will reach completion 30 months  from the time the study opens to 
accrual.  
Study Drugs  Defibrotide 6.25mg/kg IV Q6h for [ADDRESS_988017], as defined in the protocol.  
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page [ADDRESS_988018] study to evaluate safety and efficacy of defibrotide in pediatric 
patients for prevention of severe TMA . 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page [ADDRESS_988019] aspartate aminotransferase  
ATC Anatomical Therapeutic Chemical (Classification System)  
AUC  
BCH -SF 
BMT  area under the curve  
Benioff Children’s Hospi[INVESTIGATOR_307] - San Francisco  
bone marrow transplant  
BUN  blood urea nitrogen  
CBC  
CH50  complete blood cell  (count)  
complement activity  
CHR  Committee on Human Research (UCSF IRB)  
CR complete response  
CRC  Clinical Research Coordinator  
CRF case report form  
CSF cerebral spi[INVESTIGATOR_723549] -free survival  
DLT dose limiting toxicity  
DSMP  Data and Safety Monitoring Plan  
FCBP  female of childbearing potential  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
HBV hepatitis B v irus 
HCT 
HSCT  hematocrit  
hematopoietic  stem cell transplant  
HCV  hepatitis C virus 
HGB  hemoglobin  
HIV human immunodeficiency virus  
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page [ADDRESS_988020]  
MedDRA  Medical Dictionary for Regulatory Activities   
MRI magnetic resonance i maging  
MTD  maximum tolerated dose  
NCI National Cancer Institute  
ORR  
PAI-1 overall response rate  
plasminogen activator inhibitor – 1 
PD disease progression  
PK pharmacokinetics  
PO per os  (by [CONTACT_1966], orally)  
PR 
PRES  partial response  
posterior reversible encephalopathy syndrome  
PRC  
PT 
PTT Proto col Review Committee (UCSF)  
prothrombin time  
partial thromboplastin time  
QOL  Quality of Life  
RBC  
SAE red blood cell (count)  
serious adverse event  
SD stable disease  
SD standard deviation  
SGOT  serum glutamic oxaloacetic transaminase  
SGPT  
ST2 
TBI serum glutamic pyruvic transaminase  
suppression of tumorigeneicity   
total body irradiation  
TMA  
TRM  
ULN 
WBC  thrombotic microangiopathy  
treatment related mortality  
upper limit of normal  
white blood cell (count)       
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page [ADDRESS_988021] of Abbreviations  ................................ ................................ ................................ ......................  4 
Table of Contents  ................................ ................................ ................................ ..........................  6 
1 Introduction  ................................ ................................ ................................ ............  9 
1.1 Background on Indication  ................................ ................................ ....................  9 
1.2 Background on the Compounds  ................................ ................................ ........  10 
1.3 Rationale for the Proposed Study  ................................ ................................ ...... 10 
1.4 Correlative Studies  ................................ ................................ .............................  11 
2 Objectives of the Study  ................................ ................................ .......................  11 
2.1 Primary  ................................ ................................ ................................ ...............  11 
2.2 Secondary  ................................ ................................ ................................ ..........  11 
2.3 Exploratory Objectives, Other Assessments  ................................ ......................  12 
2.4 Endpoints  ................................ ................................ ................................ ...........  12 
2.4.1  Primary Endpoints  ................................ ................................ ..........................  12 
2.4.2  Secondary Endpoints  ................................ ................................ .....................  12 
2.4.3  Exploratory Endpoints  ................................ ................................ ....................  12 
3 Study Design  ................................ ................................ ................................ ....... 12 
3.1 Characteristics  ................................ ................................ ................................ ... 12 
3.2 Number of Subjects  ................................ ................................ ...........................  12 
3.3 Eligibility Criteria  ................................ ................................ ................................  12 
3.3.1  Inclusion Criteria  ................................ ................................ ............................  13 
3.3.2  Exclusion Criteria  ................................ ................................ ...........................  13 
3.4 Duration of Therapy  ................................ ................................ ...........................  14 
3.5 Duration of Follow Up  ................................ ................................ ........................  14 
3.6 Study Timeline  ................................ ................................ ................................ ... 14 
3.6.1  Primary Completion  ................................ ................................ ........................  14 
3.6.2  Study Completion  ................................ ................................ ...........................  14 
4 Study Drugs  ................................ ................................ ................................ .........  14 
4.1 Description, Supply and Storage of Investigational Drugs  ................................ . 14 
4.1.1  Investigational Drug #1  ................................ ................................ ..................  14 
4.2 Drug Accountability  ................................ ................................ ............................  15 
4.3 Drug Ordering  ................................ ................................ ................................ .... 15 
4.4 Packaging and Labeling of Study Drugs  ................................ ............................  15 
5 Treatment Plan  ................................ ................................ ................................ .... 15 
5.1 Dosage and Administration  ................................ ................................ ................  15 
5.1.1  Dose Modifications and Dosing Delays Tables for Specific Adverse Events  . 16 
5.2 Monitoring and Toxicity Management  ................................ ................................  16 
5.2.1  Other toxicities:  ................................ ................................ ..............................  [ADDRESS_988022]-treatment/Follow Up Visits  ................................ ................................ ..... 18 
6.1.4 Discontinuation of Therapy  ................................ ................................ ............  19 
6.2 Usage of Concurrent/Concomitant Medications  ................................ ................  21 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 7 of 37 Table of Contents  
6.3 Dietary Restrictions  ................................ ................................ ............................  21 
6.4 Prohibited Medications  ................................ ................................ .......................  21 
7 Reporting and Documentation of Results  ................................ ............................  21 
7.1 Evaluation of Efficacy (or Activity)  ................................ ................................ ...... 21 
7.2 Definitions  ................................ ................................ ................................ ..........  21 
7.2.1  Definition of TMA  ................................ ................................ ............................  21 
7.2.2  Definition of Severe TMA  ................................ ................................ ...............  23 
7.3 Evaluation of Safety and Toxicity  ................................ ................................ ....... 23 
7.4 Definitions of Adverse Events  ................................ ................................ ............  23 
7.4.1  Adverse Event  ................................ ................................ ................................  23 
7.4.2  Adverse reaction  ................................ ................................ ............................  23 
7.5 Recordi ng of an Adverse Event  ................................ ................................ .........  25 
7.6 Follow -up of Adverse Events  ................................ ................................ .............  25 
7.7 Adverse Events Monitoring  ................................ ................................ ................  26 
7.8 Expedited Reporting  ................................ ................................ ..........................  26 
8 Statistical Considerations and Evaluation of Results  ................................ ..........  27 
8.1 Study End points  ................................ ................................ ................................ . 27 
8.1.1  Study Design  ................................ ................................ ................................ .. 28 
8.1.2  Randomization  ................................ ................................ ...............................  28 
8.1.3  Unblinding Subjects  ................................ ................................ .......................  28 
8.1.4  Stratification Factors  ................................ ................................ ......................  28 
8.2 Determination of Sample Size and Accrual Rate  ................................ ...............  28 
8.2.1  Sample Size and Power Estimate  ................................ ................................ .. 29 
8.2.2  Replacement Policy  ................................ ................................ .......................  29 
8.2.3  Accrual estim ates ................................ ................................ ...........................  29 
8.3 Interim Analyses and Stoppi[INVESTIGATOR_1869]  ................................ ................................  29 
8.4 Analyses Plans  ................................ ................................ ................................ .. 29 
8.4.1  Analysis Population  ................................ ................................ ........................  29 
8.4.2  Primary Analysis (or Analysis of Primary Endpoints)  ................................ ..... 29 
8.4.3  Secondary Analysis (or Analysis of Secondary Endpoints)  ............................  29 
8.4.4  Other analyses/Assessments  ................................ ................................ .........  [ADDRESS_988023] Approval  ................................ ................................ .. 30 
9.3 Informed Consent  ................................ ................................ ..............................  30 
9.4 Changes in the Protocol  ................................ ................................ .....................  30 
9.5 Handling and Documentation of Clinical Supplies  ................................ .............  31 
9.6 Case Report Forms (CRFs)  ................................ ................................ ...............  31 
9.7 Oversight and Monitoring Plan  ................................ ................................ ...........  31 
9.8 Coordinating Center Documentation of Distribution  ................................ ...........  31 
9.9 Regulatory Documentation  ................................ ................................ ................  32 
10 Protection of Human Subjects  ................................ ................................ .............  32 
10.1 Protection from Unnecessary Harm  ................................ ................................ ... 32 
10.2 Protection of Privacy  ................................ ................................ ..........................  32 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page [ADDRESS_988024] of Tables  
Table 5.1  Regimen Description  ................................ .............  Error! Bookmark not defined.  
Table 5.1.1      Adverse events : bleeding or hypersensitivty reaction  ...........  Error! Bookmark not 
defined.  
Table 6.1         Sch edule of Study Procedures and Assessments  Error! Bookmark not defined.  
Table 7.2  Clinical criteria  ................................ .......................  Error! Bookmark not defined.  
 
 
 
 
 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 9 of 37 1 Introductio n 
1.1 Background on Indication  
Hematop oietic stem cell transplant (H SCT) is associated with an appreciable degree of 
transplant -related (i.e. toxic) mortality (TRM). The incidence of TRM at [ADDRESS_988025] 
ranges from 5 -15% depending upon the stem cell source utilized  (Wingard, J Clin Oncol  2011). 
The UCSF BCH -SF BMT program has reviewed all cases of non -relapse related death from 
2012 -2015 and identified a complication of endothelial injury known as  transplant associated 
thrombotic microangiopathy  (TMA ) as the most common cause of TRM in our patient 
population.    
TMA is a multi -system disease  in which widespread endothelial injury  leads to microangiopathic 
hemolytic anemia, intravascular platelet activation and formation of thrombi within the 
microcirculation.  The endolethial injury then prom otes the complement cascade leading to 
additional injury to the endothelium further propagating the disorder.    
TMA predominantly occurs in the kidneys but can  affect  the liver, lungs, intestines and brain.  
The risk factors for the development of TMA  include myeloablative and reduced intensity 
conditioning regimens , calcineurin inhibitors (tacrolimus, cyclosporine ), mTOR inhibitors 
(sirolimus) , and infections.   Additional risk factors include mismatched donors, ABO mismatch, 
and non -Caucasian patients.  When genetic testing was performed looking at seventeen genes 
involved in the pathogenesis of other thrombotic microangiopathies, n on-Caucasian patients 
with TMA were found to have  more genetic variations when compared Caucasian patients 
(Jodele, Blood 2016 ).   
Diagnosis of TMA can be difficult as systemic signs  and symptoms  of TMA are often similar to 
other common transplant complications, such as medication induced hypertension and 
cytopenias .  Unlike in thrombocytopenic purpura, patients with TMA have nor mal ADAMTS13 
activity.    A renal biopsy would be useful in diagnosi s however is often not possible given the 
risk factors of the procedure in a transplant patient.   
The reported prevalence  of TMA is varied  likely due to diagnostic uncertainty  and center 
expertise, but large retrospective studies have reported it as 10 -39%, with the majority  of cases 
occurring in the first 100 days after transplant .  Of the patients who develop TMA, approximately 
half of them will develop severe disease.   Outcomes are poor with a reported 30 -50% mortality 
rate and as high as 80% in patients with severe disease. F urthermore, survivors of TMA  may 
have significant morbidity (e.g. renal failure and need for long -term dialysis, heart failure, and 
significantly prolonged hospi[INVESTIGATOR_063]).  
There is no gold standard of treatment for TMA.  Supportive care including renal support , 
discontinuation of calcineurin inhibitors  and treatment of infections.  Treatment options include 
plasma exchange, complement cascade blockade, and defib rotide.  Early treatment is crucial to 
decrease morbidity and mortality.    
Interestingly, our most severe cases of TMA  have occurred in patients NOT receiving 
calcineurin  inhibitors or sirolimus.  Despi[INVESTIGATOR_723550] , we hav e 
continued to see poor outcomes treating with complement blockade alone. This suggests that 
complement activation may trigger a complex cascade of parallel inflammatory mediators that 
lead to end organ damage independent of the complement pathway. Therefo re, our goal is to 
prevent TMA  whenever possible via augmentation of endothelial repair.  
 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 10 of 37 1.2 Background on the Compounds  
Refer to the Investigator’s Brochure /approved labeling for detailed background information on 
defibrotide.  
 
1.[ADDRESS_988026] -risk for the development of TMA , or high -risk, based on 
the following clinical criteria:  
1. Patients undergoing tandem autologous  transplant with thiotepa in one or more of the 
conditioning regimens .  
 
OR: 
 
2. Patients with at least 3 of the following characteristics:  
a) >10 years of age  
b) Non-Caucasian race / Hispanic eth nicity  
c) Undergoing haploidentical transplant  
d) Minor ABO Mismatch  
 
Using these criteria, we retrospectively reviewed 160 transplants performed from 1/1/13 to 
9/30/16. There were 13 cases of TMA  total (8.1%), with 7 cases (4.4%) deemed severe by [CONTACT_723559] r enal failure, development of pericardial effusion, and/or death. In the [ADDRESS_988027] -risk 
patients, there were 6 total cases of TMA , but only 1 was severe (0.7%). Conversely, in the 22 
high-risk patients there were 7 total TMA  cases, 6 of which were severe  (27.3%). Most cases 
showed evidence of evolving TMA  before Day +[ADDRESS_988028]  (Jodele Blood Rev 2015, Obut BMT 2016) . Therefore, 
the hypothesis is that in high -risk patients the administration of certain combinations of high -
dose conditioning agents (radiation and/or chemotherapy) and/or post -HSCT inflammator y 
events initiate the complement pathway to aberrantly attack the endothelium .  Although the 
current standard treatment for post -transplant microangiopathic processes involves targeting 
inflammatory mediators with complement blockade and plasmapheresis, th ese therapi[INVESTIGATOR_723551], namely, endothelial damage.  
 
Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective 
treatment in other endothelial disorders such as hepatic veno -occlusive disease (Richardson 
Blood 2002).  It is a polydeoxyribonucleotide salt that blocks plasminogen activator inhibitor -1 
(PAI-1) and attenuates the effect  of tumor necrosis factor.  It also increases prostaglandin E2 
and prostacy clin levels which alters the platelet activity adhesion and aggregation and relaxes 
the smooth muscle of blood vessel walls.  All of this likely protects the endothelium from 
damage. Yeates  et al have shown that patients with TMA  who were treated with defi brotide had 
a 77% response rate. (Yeates et al , Bone Marrow Transplantation, 2017 ).   
 
The use of defibrotide in the context of VOD treatment and prevention has been studied 
extensively.  A landmark report  showed that defibrotide given to children during s tem cell 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page [ADDRESS_988029] disease  (Corbacioglu, Lancet 2012).  However, there has 
not been a prospective study to show that such prophylaxis  is effective in the prevention of 
TMA . 
 
1.4 Correlative Studies  
Biomarkers indicative of endothelial damage and TMA  activity will be drawn to assess 
subclinical TMA  activity as well as risk for subsequent development of TMA  while on defibrotide.  
These include  plasma free hemoglobin (UCSF clinical lab), suppression of tumorigeneicity (ST2, 
Viracor), angio poietin 2 (Ang2, Myriad), and plasminogen activator inhibitor – 1 (PA I-1, Quest) .  
Study labs will be assessed at 4 time points prior to  Day +21, and at diagnosis of TMA .   
Hypothesis:  
1. The i ncidence of TMA  will correlate with  increase s in one or more  of these 
biomarkers over baseline at any time post -HSCT.   
2. The severity of TMA  will correlate with a maximum increase in one or more of 
these biomarkers.  
This will provide a predictive basis for future patients who may require preemptive treatment of 
early / p reclinical TMA . 
 
2 Objectives of the Study  
2.1 Primary  
• To determine the safety and feasibility of administering prophylactic Defibrotide 
(provided by [CONTACT_156239]) to a pi[INVESTIGATOR_723552] -risk 
for the development of severe TMA  following H SCT.  Safety to be determined with 
regard to bleeding risk and risk of hypersensitivity reaction. Feasibility to be determined 
with regard to administration concurrently with chemotherapy and supportive 
medications before, during, and after stem  cell infusion  
2.2 Secondary  
• To determine if administration of prophylactic Defibrotide will prevent the development of 
TMA  in clinically high -risk patients compared to historic controls.   
o Incidence of TMA  in the first [ADDRESS_988030] will be compared to in cidence 
in a similar cohort of historical controls.  
o Incidence of severe TMA  as defined by [CONTACT_723560]:  
▪ Renal dysfunction requiring dialysis  
▪ Pleural or pericardial effusion requiring any medical or surgical 
intervention  
▪ CNS dys function including seizure , PRES  
▪ Death  
 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 12 of 37 2.3 Exploratory Objectives, Other Assessments  
• Biomarker specimens will be drawn at 4 time points prior to development of TMA .  
Values will be analyzed to determine whether any one biomarker or a combination of 
biomarkers  may be predictive of TMA  development or severity.  
 
2.4 Endpoints  
2.4.1  Primary Endpoints  
• Incidence of missed doses of defibrotide  
• Incidence of reportable  SAE’s  
• Incidence  of clinically significant bleeding requiring discontinuation of therapy  
• Incidence of hypersensitivity reaction  requiring discontinuation of therapy  
 
2.4.2  Secondary Endpoints  
• Incidence of TMA  as diagnosed by [CONTACT_723561] 7.2 .1. 
• Incidence of severe  TMA  as diagnosed by [CONTACT_723562] 7.2.2.  
2.4.3  Exploratory Endpoints  
• Incidence of elevation of single or combination of biomarkers predictive of development 
of TMA  
 
[ADDRESS_988031] b e obtained 
from the patient prior to enrollment.  The following criteria apply to all patients enrolled onto the 
study unless otherwise specified.  
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 13 of 37 3.3.1  Inclusion  Criteria  
1. Age 0 -30 years of age  
2. Life expectancy > 6 months  
3. ECOG or Karnofsky Performance Status >[ADDRESS_988032] meet TMA  High-Risk criteria  
A. Patients undergoing tandem autologous transplant with thiotepa in one or 
more of the conditioning regimens.  
 
OR: 
B. . Patients with at least 3 of the following characteristics:  
a. >10 years of age  
b. Non-Caucasian race/ Hispanic ethnicity  
c. Undergoing haploidentical transplant  
d. Minor ABO Mismatch  
 
6. The effects of defibrotide on the developin g human fetus are unknown.  For this reason 
and because other therapeutic drugs used as a part of transplant  are known to be 
teratogenic, women of child -bearing potential and men must agree to use adequate 
contraception: abstinence per institutional stem c ell transplantation guidelines, for the 
duration of study participation and for a minimum of [ADDRESS_988033] dose of study drug.   
7. Ability to unders tand a written informed consent document, and the willingness to sign it  
 
3.3.2  Exclusion Criteria  
1. Age >30 years  
2. Life expectancy < 6 months  
3. Known bleeding diathesis or bleeding risk deemed by [CONTACT_723563] a 
contraindication  to administration of a nticoagulants.  
4. Known hypersensitivity reaction to defibrotide  
5. Any patient not meeting TMA  High-Risk criteria as defined in section 1.3  
6. Pregnant women are ex cluded from this study because they will be receiving teratogenic 
therapy as part of the stem cell t ransplant.  
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 14 of 37 3.4 Duration of Therapy  
In the absence of treatment delays due to adverse events, treatment should  begin the day prior 
to initiation of conditioning and continue until Day +[ADDRESS_988034], or:  
• Disease progression  
• Inter-current illness that prevents f urther administration of treatment  
• Unacceptable adverse event(s)  
• Patients decides to withdraw from the study  
• Significant patient non -compliance with protocol  
• General or specific changes in the patients’ condition render the patient unacceptable for 
further  treatment in th e judgment of the investigator.  
3.[ADDRESS_988035].  
Patients removed from study for unacceptable treatment related adverse event(s) will be 
followe d until resolution or stabilization of  all treatment -related  adverse event s to Grade 2 or 
lower.  
3.6 Study Timeline  
Accrual is estimated to begin in Fall 2017 and continue through Fall 2019.   Patients will be 
followed for  safety and efficacy through Spring 202 0.   
3.6.1  Primary Completion  
The study will reach primary completion 24 months from the time the study opens to accrual.  
3.6.2  Study Completion  
The study will reach study completion 30 months from the time the study opens to accrual.  
4 Study Drugs  
4.1 Description, Supply a nd Storage of Investigational Drugs  
4.1.1  Investigational Drug #1  
Defibrotide  is available as a solution, Intravenous, as sodium [preservative free]:  Defitelio: 200 
mg/2.5 mL (2.5 mL) .  Refer to the package insert for complete information.  
 
Classification :  
Therapeutic Category: Antiplatelet Agent; Thrombolytic Agent  
 
Mechanism of Action :   
Defibrotide augments plasmin enzymatic activity to hydrolyze fibrin clots. It reduces endothelial 
cell (EC) activation and increases EC -mediated fibrinolysis by [CONTACT_723564], as well as by [CONTACT_723565] -1 expression.  
 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 15 of 37 Metabolism :   
Polynucleotides are metabolized via nucleases, nucleotidases, nucleosidases, deaminase s, and 
phosphorylases to oligonucleotides, nucleotides, nucleosides, and then to the free 2’ -
deoxyribose sugar, purine and pyrimidine bases  
 
Contraindications :   
Known hypersensitivity to defibrotide or any component of the formulation; concomitant 
adminis tration with systemic anticoagulant or fibrinolytic therapy  
 
Availability :   
FDA approved March [ADDRESS_988036] vials at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C 
(59°F to 86°F). Solutions diluted for in fusion in D5W or NS should be used within [ADDRESS_988037] partially used vials.  Side  
 
Effects  
Complete and updated adverse event information is available in the Inves tigational Drug 
Brochure and/ or product package insert .  
 
4.[ADDRESS_988038] will manage drug accountability records.  
4.3 Drug Ordering  
UCSF will obtain defibrotide  directly from pharmace utical company as study supply.  
4.4 Packagin g and Labeling of Study Drugs  
Drugs will be packaged and labeled per UCSF institutional standards, adhering to applicable 
local and federal laws.  
5 Treatment Plan  
5.1 Dosage and Administration  
Treatment will be administered on a n inpatient basis.  Table 5. 1 Regimen Description  
Study Drug  Premedication; 
precautions  Dose  Route  Schedule  Cycle Length  
Defibrotide  None  6.25 mg/kg  IV over 2 hours  Q6h Day prior to start of 
conditioning through 
Day +[ADDRESS_988039]  
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 16 of 37 5.1.1  Dose Modifications and Dosing Delays Tables for Specific Adverse Events  
Adverse Event:  Bleeding or Hypersensitivi ty reaction  
Grade of Event  Management  
≤ Grade 1  No change in dose  
Grade 2  Hold until ≤  Grade 1  
Resume at same dose level  
Grade 3  Discontinue therapy  
Grade 4  Discontinue therapy  
*Patients requiring a delay of >  [ADDRESS_988040] 
degree of toxicity.  
We will monitor for incidence of clinically signific ant bleeding and hypersensitivity reactions:  
Hemorrhage: Defibrotide may increase the risk of bleeding (based on increased activity of 
fibrinolytic enzymes  in vitro ). Do not initiate therapy in patients with active 
bleeding ; monitor closely for signs of bl eeding. If hemodynamically significant 
bleeding develops while on therapy, discontinue defibrotide, evaluate/treat the 
underlying cause, and provide supportive care until bleeding resolves.  
Hypersensitivity reactions: Hypersensitivity reactions ( e.g., rash , urticaria, and 
angioedema) have been reported (rare). One patient with a history of previous 
defibrotide exposure experienced an anaphylactic reaction. Monitor closely for 
hypersensitivity reactions, particularly in patients who have received defibrotide  
previously. Discontinue therapy for severe hypersensitivity reactions and treat 
accordingly; monitor until symptoms resolve.  
Acute toxicity will be managed by [CONTACT_723566][INVESTIGATOR_723553].  Hypersensitivity reacti ons will be managed per local protocols and standard of 
care.  Further management will depend upon the judgment of the c linician . 
5.2.1  Other toxicities :  
The toxicities listed below have been reported in patients receiving defibrotide.  None have been 
directly attributable to defibrotide itself.  
Cardiovascular: Hypotension, thrombophlebitis  
Central nervous system: Cerebral hemorrhage, intracranial hemorrhage  
Endocrine & metabolic: Hot flash, hyperuricemia  
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 17 of 37 Gastrointestinal: Abdominal cramps, abdominal pain, blood y diarrhea, diarrhea, gastrointestinal 
hemorrhage, hematemesis, nausea, vomiting  
Genitourinary: Hematuria  
Hematologic & oncologic: Hemorrhage, oral hemorrhage, pulmonary hemorrhage  
Hypersensitivity: Hypersensitivity reaction  
Immunologic: Graft versus host disease  
Infection: Infection, sepsis  
Renal: Renal failure  
Respi[INVESTIGATOR_696]: Epi[INVESTIGATOR_3940], pneumonia, pulmonary alveolar hemorrhage, pulmonary infiltrates  
Miscellaneous: Fever  
 
[ADDRESS_988041].  Any results falling outside of the reference 
ranges may be repeated at the discretion of the investigator. All on -study visit procedures are 
allow ed a window of ±  2 days  unless otherwise noted .  Treatment or visit delays for public 
holidays or  weather conditions do not constitute a protocol violation.  
A written, signed, informed consent form (ICF) and a Health Insurance Portability and 
Accountability Act (HIPAA) authorization must be obtained before any study -specific 
assessments are initiated.   A copy of the signed ICF  will be given to the subject and a copy will 
be filed in the medical record.  The original will be kept on file with the study records.   
All patients who are consented will be registered in the study database.  The system is 
password protected and meets HIPAA requirements.  
Patients undergoing tandem autologous transplants will repeat the schedule of procedures and 
assessments on admission for second transplant.   
6.1.1  Pretreatment Period  
[IP_ADDRESS]  Screening Assessments   
The Screening procedures  and assessment s must be completed within 28 days prior to 
admission.  
• Physical examination  
• Vital signs  
• Performance Status  
• Patient and donor blood type, if eligible  
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 18 of 37 6.1.2  Treatment Period  
[IP_ADDRESS]  Study Procedures: Treatment (Day of admission through Day +[ADDRESS_988042])  
These procedures must be completed weekly starting the day before the start of alkylating 
agents or TBI.  
• Defibrotide 6.25mg/kg IV Q6h to start at 9 pm (+/- 3 hours) on the day prior to start of 
conditioning . 
• Evaluation of clinical response or deterioration  
• Physical examination  
• Vital signs  
• Performance Status  
• Evaluation of adverse events  
• Standard labs including  
o CBC with differential and platelet count , reticulocyte count  
o Blood chemistry assessment, including: alkaline phosphatase, ALT/AST, total 
bilirubin, ca lcium, phosphorus, magnesium, BUN, creatinine, total protein, 
albumin, fasting glucose, potassium, sodium, chloride, bicarbonate  
o Uric acid, LDH  
o Direct antiglobulin test, peripheral smear for RBC morphology,  
o Urine protein concentration, urine protein / cre atinine ratio,  
o Complement activity (CH50)  
o Coagulation panel including PT/PTT , d-dimer  
6.1.[ADDRESS_988043] -treatment/Follow Up Visits  
Patients will be followed weekly until Day +28 then monthly  for up to 6 months  after enrollment 
or until disease progression ; exception f or patients receiving tandem transplants will be followed 
weekly until Day +28 then monthly  for up to 6 months after admission from second transplant  or 
until disease progression .  The following procedures will be performed  at the Follow Up Visit(s) : 
• Evalu ation of clinical response or deterioration  
• Physical examination  
• Vital signs  
• Performance Status  
• Evaluation of adverse events  
• Standard labs including  
o CBC  with differential and platelet count , reticulocyte  count  
o Blood chemistry assessment, including:  alkali ne phosphatase, ALT/AST, total 
bilirubin, calcium, phosphorus,  magnesium,  BUN, creatinine, total protein, 
albumin, glucose, potassium, sodium, chloride, bicarbonate  
o Uric acid , LDH, haptoglobin  
o Direct antiglobulin test , peripheral smear for RBC morphology  
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 19 of 37 o Urine protein concentration, urine protein / creatinine ratio  
o Complement activity ( CH50 ) 
o Coagulation panel  including PT/PTT , d-dimer  
6.1.4  Discontinuation of Therapy  
The Investigator will withdraw a patient whenever continued participation is no longer in the 
patient’s best interests.  Reasons for withdrawing a patient include, but are not limited to, 
disease progression, the occurrence of an adverse event or a concurrent illness, a patient’s 
request to end participation, a patient’s non -compliance or simply sig nificant uncertainty on the 
part of the Investigator that continued participation is prudent.  There may also be administrative 
reasons to terminate participation, such as concern about a patient’s compliance with the 
prescribed treatment regimen  
 
 
Version date:   2/27/2018  Protocol  #: Protocol  #:  
Phase II – Study drug(s)  Page 20 of 37  
Table 6.1: Schedule of Study Procedures and Assessments4 
 Screen  Days Pre -HSCT  Days Post -HSCT  Weeks Post -HSCT  TMA  Dx 
(+/- in 
days)  Admit 
(-28) Admit  
 -7 
(+/- 2) -1 
(+/- 1) 7 
(+/- 2) 14 
(+/- 2) 21 
(+/- 2) 28 
(+/- 2) 8 
(+/- 7) 12 
(+/- 7) 16 
(+/-7) 20  
(+/- 7) 24 
(+/-7) Dx  
(+/-3) 
Informed 
consent  x              
AE 
assessment   x x x x x x x x x x x x x 
Defibrotide   x x x x x x       +/- 
Physical 
exam  *  x x x x x x x x x x x x x 
Vital signs  *  x x x x x x x x x x x x x 
Medical 
History  *  x x x x x x x x x x x x x 
Standard 
Labs1 *  x x x x x x x x x x x x x 
Study Labs2  x3  x x  x       x 
               
1. Labs per standard of care should include CBC, complete c hemistry, LDH,  uric acid,  haptoglobin, direct antiglobulin test, peripheral smear  
for RBC morpholo gy, urine protein concentration, urine protein / creatinine ratio, CH50, coagulation panel .  
2. Study labs to include plasma free H gb, ST2, Ang -2, PAI -1, and hold specime n.  
3. +/- 2 day window  
4. Patients undergoing tandem autologous transplants will repeat the sc hedule of procedures and assessments on admission  
for second transplant , with the exception of screening .   
* Standard of care for patients undergoing HSCT  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 21 of 37 6.2 Usage of Concurrent /Concomitant  Medications  
 
Patients on the trial will receive the UCSF  standard of care for high risk TMA  
• Vitamin D started prior to admission with goal levels of  vitamin D, 25 hydroxy 
level of 30 - 60ng/mL  
• Allopurinol  on admission and continue until Day 0 if uric acids are normal, or 
longer if uric acids remain high  
• Two weeks prior to  admission  patients will begin Eicosapentaenoic Acid (EPA, a 
component of fish oil). (dosing:  < 6 months: 110 mg PO qday, 6 months – 17 
years: 30 mg/kg/day, max 2000 mg/day) divided up to three times per day) which 
will continue until day +100.  EPA will b e held when patient is unable to take 
PO, during periods when the patient’s platelet count is < 20 x 10^9/L, for clinical 
bleeding, prior to procedures (hold at least 4 days prior to procedure) , and/or 
requiring platelets transfusions.  Clinical trial evid ence for EPA does not support 
an increased bleeding risk with fish oil therapy,  even when used in combination 
with other agents that may increase bleeding.  
•  n-Acetylcysteine (NAC) prophylaxis in addition to those doses given on 
admission, and Day +1 and Da y +2 for VOD prophylaxis will be given as  70 
mg/kg (rounded to nearest vial size) every 8 hours IV or PO starting day +3 and 
continued until Day +42 or discharge, whichever comes sooner.  
 
There are no restrictions in concurrent / concomitant medications ex cept per standard of care 
recommendations for use of defibrotide.  Specifically, tissue plasminogen activator (t -PA) is 
contraindicated due to bleeding risk; use of low doses for clearance of IV catheters is permitted. 
Administration of other anticoagulant s concurrently with defibrotide is at the discretion of the 
treating physician.  
6.3 Dietary Restrictions  
None  
6.4 Prohibited Medications  
Eculiz umab if used as prophylaxis for TMA , Ibuprofen or other NSAIDs, aspi[INVESTIGATOR_248]  
7 Reporting and Documentation of Results  
7.1 Evaluation  of Efficacy  (or Activity)  
Incidence of TMA  will be calculated on a rolling basis and at completion of the study.  If at any 
time incidence of TMA  exceeds 2 patients , the study will be paused and evaluated for futility.  
7.2 Definition s 
7.2.1  Definition  of TMA  
Criter ia for diagnosis of TMA  for purposes of this study will be as follows:  
• Evidence of microangiopathy , with an additional item from Category A or B , OR 
o The presence of schistocytes (>2/HPF) in the peripheral blood, or  
o Histologic evidence of microangiopathy on  a tissue specimen, or  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 22 of 37 o Undetectable haptoglobin with increased reticulocyte count  
• No evidence of microangiopathy but:  
o 1 item from Category A (evidence of organ dysfunction), AND  
o 3 items from Category B (increased TMA  biomarkers)  
 
Category A (clinical marke rs / organ dysfunction)  Category B (biomarkers)  
• Proteinuria  
• Hypertension  
• Renal dysfunction  • De novo anemia  
• Do novo thrombocytopenia  
• Elevated LDH  
• Terminal Complement Activation  
*Definitions of these criteria are provided below.  
 
Definitions of criteria ar e adapted from Jodele et al (2015 Blood Rev) and provided below:  
Laboratory or clinical marker  Description  
1. Lactate dehydrogenase (LDH)  • Elevated above the upper limit of normal for 
age 
2. Proteinuria  • A random urinalysis protein concentration of 
≥30 mg/dL  or abnormal Pr/Cr Ratio  
3. Hypertension  • <18 years of age: a blood pressure at the 
95th percentile value for age, sex and 
height.  
• ≥18 years of age: a blood pressure ≥140/90 
mm Hg.  
4. De novo thrombocytopenia  • Thrombocytopenia with a platelet count <50 
× 109/L or a ≥50% decrease in the platelet 
count  
5. De novo anemia  • A hemoglobin below the lower limit of 
normal for age anemia requiring transfusion 
support  
6. Evidence of microangiopathy  • The presence of schistocytes (>2/HPF) in 
the peripheral blood , or 
• histologic evidence  of microangiopathy on a 
tissue specimen , or 
• Undetectable haptoglobin with increased 
reticulocyte count  
7. Terminal complement activation  • Elevated plasma concentration of sC5b -9 
above upper normal laboratory limit  
8. Renal dysfunction  • Elevated creatinine above  upper limit of 
normal not due to alternative cause (e.g., 
drug, fluid status)  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 23 of 37  
7.2.2  Definition of Severe TMA  
Any TMA  meeting criteria described in 7.2.1 with any of the following additional features:  
• Renal dysfunction requiring dialysis  
• Pleural or pericardi al effusion requiring any medical or surgical intervention  
• CNS dysfunction including seizure  
• Inpatient admission > [ADDRESS_988044] one dose of study drug.  The 
study will use the CTCAE v4.03 for reporting of non -hematologic adverse events and modified 
criteria for hematologic adverse events . 
 
7.4 Definitions of Adverse Events  
7.4.1  Adverse Event  
An adverse event (also known as an adverse experience) is defined as any untoward medical 
occurrence associated with the use of a drug in humans, whether or not considered dr ug 
related.  More specifically, an adverse event  (can be any unfavorable and unintended sign (e.g., 
an abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
drug, without any judgment about causality.  An adverse event c an arise from any use of the 
drug (e.g., off -label use, use in combination with another drug) and from any route of 
administration, formulation, or dose, including an overdose.  
7.4.2  Adverse reaction  
An adverse reaction is defined as any adverse event caused by  [CONTACT_2224] a drug.  Adverse 
reactions are a subset of all suspected adverse reactions for which there is reason to conclude 
that the drug caused the event.  
[IP_ADDRESS]  Suspected  
A suspected adverse reaction is defined as any adverse event for which there is a reason able 
possibility that the drug caused the adverse event. For the purposes of IND safety reporting, 
“reasonable possibility” indicates that there is evidence to suggest a causal relationship 
between the drug and the adverse event.  A suspected adverse react ion implies a lesser degree 
of certainty about causality than an adverse reaction.  
[IP_ADDRESS]  Unexpected   
An adverse event or suspected adverse reaction is considered unexpected  if it is not listed in 
the investigator brochure or package insert(s), or is not listed a t the specificity or severity that 
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 24 of 37 has been observed, or, if an investigator brochure is not required or available, is not consistent 
with the risk information described in the general investigational plan or elsewhere in the current 
application.  
“Unexpec ted,” as used in this definition, also refers to adverse events or suspected adverse 
reactions that are mentioned in the investigator brochure as occurring with a class of drugs or 
as anticipated from the pharmacological properties of the drug, but are not  specifically 
mentioned as occurring with the particular drug under investigation.  
Adverse events that would be anticipated to occur as part of the disease process are 
considered unexpected for the purposes of reporting because they would not be listed in the 
investigator brochure.  For example, a certain number of non -acute deaths in a cancer trial 
would be anticipated as an outcome of the underlying disease, but such deaths would generally 
not be listed as a suspected adverse reaction in the investigator brochure.  
Some ad verse events are listed in the Investigator B rochure  as occurring with the same class 
of drugs, or as anticipated from the pharmacological properties of the drug, even though they 
have not been observed with the dru g under investigation.  Such events would be considered 
unexpected until they have been observed with the drug under investigation. For example, 
although angioedema is anticipated to occur in some patients exposed to drugs in the ACE 
inhibitor class and an gioedema would be described in the investigator brochure as a class 
effect, the first case of angioedema observed with the drug under investigation should be 
considered unexpected for reporting purposes.  
[IP_ADDRESS]  Serious  
An adverse event or suspected adverse reacti on is considered serious  if, in the view of either 
the investigator or sponsor  (The University of [LOCATION_004], San Francisco), it results in any of the 
following outcomes:  
• Death  
• Life-threatening adverse event  
• Inpatient hospi[INVESTIGATOR_27588]  
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life function  
• Congenital anomaly/birth defect  
Important medical events that may not result in death, are life -threatening, or require 
hospi[INVESTIGATOR_708], based upon appropriate medical judgment, 
they may jeopardize the patient or subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition.  Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of 
drug dependency or drug abuse.  
[IP_ADDRESS]  Life-threateni ng 
An adverse event or suspected adverse reaction is considered life-threatening  if, in the view of 
either the investigator or sponsor, its occurrence places the patient or subject at immediate risk 
of death. It does not include an adverse event or suspect ed adverse reaction that, had it 
occurred in a more severe form, might have caused death.  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 25 of 37 7.5 Recording of an Adverse Event  
All grade 3 and above a dverse events will be entered into the study database , whether or not 
the event is believed to be associated wit h use of the study  drug.  Safety data (SAEs) will be 
collected from the time of admission until the day after completion of defibrotide (6 -12 times the 
half-life of the study drug). Data about these events and their severity will be recorded using the 
NCI CTCAE  v4.0.   
The Investigator will assign attribution of the possible association of the event with use of the 
investig ational drug, and this information will be entered into the study database  using the 
classification system listed below:  
Relationship  Attribution  Description  
Unrelated to investigational 
drug/intervention  Unrelated  The AE is clearly NOT related to the  
intervention  
Unlikely  The AE is doubtfully related to the 
intervention  
Related to investigational 
drug/intervention  Possible  The AE may be related to the intervention  
Probable  The AE is likely related to the intervention  
Definite  The AE is clea rly related to the intervention  
 
Signs or symptoms reported as adverse events will be graded and recorded by [CONTACT_40607] .  When specific adverse events are not listed in the CTCAE they will be 
graded by [CONTACT_40608], mild, moderate  or severe  according to the following grades 
and definitions:  
Grade 0  No AE (or within normal limits)  
Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated  
Grade 2  Moderate; min imal, local, or noninvasive intervention (e.g., packing, cautery) 
indicated; limiting age -appropriate instrumental activities of daily living (ADL)  
Grade 3:  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_226898]; disabling; limiting self -
care ADL  
Grade 4:  Life-threatening consequences; urgent intervention indicated  
Grade 5:  Death related to AE  
 
7.[ADDRESS_988045] with the investigational drug may 
be conducted if considered both safe an d ethical by [CONTACT_737].  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 26 of 37 7.7 Adverse Events Monitoring  
All adverse events, whether or not unexpected, and whether or not considered to be associat ed 
with the use of the study drug, will be entered into the study database , as noted above.  
The Investigator will assess all adverse events and determine re portability requirements to the 
UCSF’s Institutional Review Board, the Committee on Human Research ( CHR) . 
All adverse events entered into the study database  will be reviewed by [CONTACT_723567] 
a monthly  basis.  The Study Committee will review and discuss at each m eeting the selected 
toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the 
admini stration of the study drug(s).  
All grade(s) 3 -5 adverse events entered into the study database  will be reviewed on a monthly 
basis at th e Study Committee meetings. The Site Committee will review and discuss the 
selected toxicity, the toxicity grade, and the attribution of relationship of the adverse event to the 
administration of the study drug(s).  
In addition, all suspected adverse reacti ons considered “serious” entered into the study 
database , will be reviewed and monitored by [CONTACT_723568], which take place every eight weeks.  
 
7.[ADDRESS_988046] 
administration of the study drug(s) and it is determined to be related either to the study drug(s) 
or to a study procedure, the Investigator or his/her designee must notify the study Chair (or 
qualified alternate) within [ADDRESS_988047] may be by 
[CONTACT_14223] e -mail.  
Reporting to UCSF Committee on Human Research  (Institutional Review Board)  
The Principal Investig ator must report events  meeting the UCSF CHR definition of 
“Unanticipated Problem” (UP) within 10 business days of his/her awareness of the event.   
Expedited Reporting to the Food and Drug Administration  
If the study is being conducted under an IND, the Sponsor -Investigator is responsible for 
determini ng whether or not the suspected adverse reaction meets the criteria for expedited 
reporting in accordance with Federal  Regulations (21  CFR §312.32).  
The Investigator must report in an IND safety report any suspected adverse reaction that is both 
serious a nd unexpected.  The Sponsor -Investigator needs to ensure that the event meets all 
three definitions:  
• Suspected adverse reaction (as defined in 6.1.3 0) 
• Unexpected (as defined in 0) 
• Serious (as defined in 6.1.5)  
If the adverse event does not meet all three of the definitions, it should not be submitted as an 
expedited IND safety report.  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 27 of 37 The time line for submitting an IND safety report to FDA is no later than 15 calendar  days  after 
the Investigator determines that the suspected adverse reaction qualifies for reporting (21 CFR 
312.32(c)(1)).  
Any unexpected fatal or life -threatening suspected adverse reaction will be reported to FDA no 
later than 7 calendar days  after the Investigator’s initial receipt of the info rmation (21 CFR 
312.32(c)(2)).  
Any relevant additional information that pertains to a previous ly submitted IND safety report will  
be submitted to FDA as a Follow -up IND Safety Report without delay, as soon as the 
information is available (21 CFR 312.32(d)(2)).  
Reporting  to Pharmaceutical Companies providing Study Drug  
• Reporting to Jazz  Pharmaceuticals  
o The SI must send all SAEs (initial and follow -up) that require collection and 
reporting per protocol, and which occu r in a subject who received a Jazz 
Pharmaceuticals  product as study drug, to the J azz Pharmaceuticals  Drug Safety 
Department within 1 business day of their awareness of the SAE 
([EMAIL_6689] ). 
o The SI will report the SAEs using a US -FDA Form 3500A (MedWatch form). 
[Note: the MedWatch form, is available at 
http://www.fda.gov/downloads/Safety/MedWatch/HowToReport/DownloadForms/
UCM082728.pdf ] 
o The SI must also provide J azz Pharmaceuticals  Drug Safet y Department 
([EMAIL_13849] ) with a copy of all submissions made to the FDA at 
the time the submission is made.  
o In addition, all other adverse events will be reported to the J azz Pharmaceuticals 
Drug S afety Department in summary or line -item form upon J azz 
Pharmaceutical s’ request and at the conclusion of the study.  
 
8 Statistical Considerations and Evaluation of Results  
8.1 Study Endpoints  
• Open lab el non -randomized un -blinded study to determine feasibility, safety, and 
efficacy.  
• Feasibility endpoints;  
o Incidence of discontinuation of defibrotide. Study will be suspended if defibrotide 
is not tolerated as outlined below:  
N (accrued)  0-6 7-12 13-18 19-24 
Evaluate if discontinued in this many or 
more patients : 5 8 10 12 
 
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 28 of 37 • Safety endpoints  
o Incidence of reportable SAE’s (possibly drug -related and severe or unexpected).  
Study will be suspended if reportable AE’s  
N (accrued)  0-6 7-12 13-18 19-24 
Evaluate  if drug-related SAE’s occur  in 
this many or more patients : 4 7 10 12 
 
• Incidence of TMA  
o Historical incidence: 7 of 22 (31.8%) . With N=24, study will have 80% power to 
detect a stati stically significant difference if incidence in this treated cohort is 8% 
or less.  
o Study will be re -evaluated  if 2 patients develop TMA  as this will render the 
secondary endpoint futile . May continue enrollment to determine feasibility and 
safety  or expand the patient cohort .    
• Incidence of Severe TMA  
o Historical incidence: 6 of 22 (27.3%) . With N=24, study will have 7 0% power to 
detect a statistically significant difference if incidence in this treated cohort is 4% 
or less.  
o Study will be re -evaluated if 1 patient develops severe TMA  as this will render the 
secondary endpoint f utile. May continue enrollment to determine feasibility and 
safety  or expand the patient cohort .    
8.1.1  Study Design  
Single arm un -blinded non -randomized Phase II study.  
8.1.2  Randomization  
No randomization  is planned.  
8.1.3  Un-blinding Subjects  
No blinding is planned.  
8.1.4  Stratification Factors  
No stratification is required; all patients will receive the same treatment and follow the same 
assessment procedures.  
8.2 Determination of Sample Size and Accrual Rate  
Based on historical controls, we estimate accrual of 12 patients p er year, with a goal of 24 
patients by 2 years.  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 29 of 37 8.2.1  Sample Size and Power Estimate  
Assuming an historical rate of severe TMA  of 28% , alpha =5%, and N=24, power to detect a 
statistically  significant value of 4% in this cohort is 92%. The m inimum number of patie nts to 
enroll to achieve 80% power to detect a difference, assuming a 4% incidence in this cohort, is 
N=19.  Assuming a sample size of N=24, the study has 80% power to detect a statistically 
significant difference if the incidence of severe TMA  in this tre ated cohort is <5%.  Given the 
small sample size, adjustments for multiple comparisons will not be made.  
8.2.[ADDRESS_988048] defibrotide toxicity or failure 
of feasibility  will be replaced  with additional patients.  This included patients who are no longer 
evaluable for TMA  due to mortality prior to week 24.  
8.2.3  Accrual estimates  
Based on historical rates we estimate accrual of 12 patients per year.  
8.3 Interim Analyses and Stoppi[INVESTIGATOR_723554] 8.1.  
8.4 Analyses Plans  
8.4.1  Analysis Population  
The analysis populatio n will include all the p atients who enroll  that receive  defibrotide.  
8.4.2  Primary Analysis  (or Analysis of Primary Endpoints)  
The pr imary efficacy analysis will be performed using the ITT population. The primary endpoint 
will asses s the s afety and feasibility of defibrotide .  It will compare how many patients received 
the drug versus how many  were  intended  to receive it .  It will look into how many patients 
stopped the drug early and reasons for this.   
8.4.3  Secondary Analysis (or Analysis of Secondary Endpoints)  
This will include the incidence of TMA in the patients enrolled on study compared to historical 
controls, including their demograp hics, underlying diagnosis, conditioning regimens and other 
transplant complications.  Also will compare incidence of severe TMA compared to historical 
controls and the complications.   
8.4.4  Other analyses/ Assessments  
Other analysis  include incidence of TMA by [CONTACT_2006] +[ADDRESS_988049] , non-relapse mortality by [CONTACT_2006] 
+100 and by [CONTACT_2006] +[ADDRESS_988050] one dose of study drug.  The 
study will use the NCI CTCAE v4.03. 
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page [ADDRESS_988051] their origin in the 
Declaration of Helsinki as stated in 21 CFR §312.120(c)(4); consistent with GCP and all 
applicable regulato ry requirements.  
Before initiating this trial, the Investigator will have written and dated approval from the 
Institutional Review Board for the protocol, written informed consent form, subject recruitment 
materials,  and any other written information to be  provided to subjects before any protocol 
related procedures are performed on any subjects.   
The clinical investigation will not begin until either FDA has determined that the study under the 
Investigational Drug Application (IND) is allowed to proceed or  the Investigator has received a 
letter from FDA stating that the study is exempt from IND requirements.  
]The Investigator must comply with the applicable regulations in Title 21 of the Code of Federal 
Regulations (21 CFR §50, §54, and §312 ), GCP/I CH guidelines, and all applicable regulatory 
requirements.  The IRB must comply with the regulations in 21 CFR §[ADDRESS_988052] Approval  
The protocol, the proposed informed consent form, and all forms o f participant information 
related to the study (e.g. advertisements used to recruit participants) will be reviewed and 
approved by [CONTACT_14224]  (UCSF  Institutional Review Board ).  The initial protocol and all 
protocol amendments must be approved by [CONTACT_535664].   
9.[ADDRESS_988053] then notify the CHR in writing within f ive (5) working days after 
implementation.   The Study Chair  and the UCSF study team will be responsible for updating any 
participating sites.  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 31 of 37 9.5 Handling and Documentation of Clinical Supplies  
The UCSF Principal Investigator [INVESTIGATOR_80040], dispensation, return, or other disposition of all investigational drugs.  The 
date, quantity and batch or code number of the drug, and the identification of patients to whom 
study drug has been dispensed by [CONTACT_723569].  The s ponsor -
investigator will maintain written records of any disposition  of the study drug . 
The Principal Investigator [INVESTIGATOR_723555].  Furthermore, the Principal Investigator [INVESTIGATOR_14158].  
9.6 Case Report Forms (CRFs)  
The Principal Investigator [INVESTIGATOR_1238]/or his/her designee, will prepare  and maintain adequate and 
accurate participant case histories with observations and data pertinent to the study.  Study 
specific Case Report Forms (CRFs) will document safety and treatment outcomes for safety 
monitoring and data analysis.  All study data will be entered into the study database  via 
standardized CRFs in accordance with the CTMS study calendar, using single data entry with a 
secure access account.  The Clinical Research Coordinator (CRC) will complete the CRFs as 
soon as possible upon complet ion of the study visit; the Investigator will review and approve the 
completed CRFs.  
The information collected on CRFs shall be identical to that appearing in original source 
documents.  Source documents will be found in the patient’s medical records main tained by 
[CONTACT_14228].  All source documentation should be kept in separate research folders for 
each patient.  
In accordance with federal regulations, the Investigator is responsible for the accuracy and 
authenticity of all clinical and laboratory data entered onto CRFs.  The PI [INVESTIGATOR_14159].  
All source documentation and CTMS data will be available for review/monitoring by [CONTACT_174275].  
The Principal Inve stigator will be responsible for ensuring the accurate capture of study data.  At 
study completion, when the CRFs have  been declared to be complete and accurate, the 
database will be locked.  Any changes to the data entered into the CRFs after that time ca n only 
be made by [CONTACT_14230] , the Trial Statistician, and the 
Protocol Project Manager.  
9.[ADDRESS_988054] operating procedures, FDA regulations, and Good Clinical 
Practice (GCP).  Coordinating Center Documentation of Distribution   
It is the responsibility of the Study Chair to maintain adequate files documenting the distribution 
of study documents as well as their receipt (when possible). Correspondence file: should 
contain copi[INVESTIGATOR_014] (paper or electronic) of all protocol versions,  cover letters, amendment outlines 
(summary of changes), etc., along with distribution documentation and (when available) 
documentation of receipt.  
Correspondence log: should be a brief list of all documents distributed including the date sent, 
recipi[INVESTIGATOR_841](s ), and (if available) a tracking number and date received.  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page [ADDRESS_988055] be approved by [CONTACT_723570] (CHR). Prior to implementing this protocol at the participa ting sites, 
approval for the UCSF CHR approved protocol must be obtained from the participating site’s 
IRB.  
[ADDRESS_988056]’s rights and welfare are protected and that the potential ben efits and/or the importance 
of the knowledge to be gained outweigh the risks to the individual. The CHR also reviews the 
informed consent document associated with each study in order to ensure that the consent 
document accurately and clearly communicates t he nature of the research to be done and its 
associated risks and benefits.  
10.2 Protection of Privacy  
Patients will be informed of the extent to which their confidential health information generated 
from this study may be used for research purposes. Following  this discussion, they will be asked 
to sign the HIPAA form and informed consent documents. The original signed document will 
become part of the patient’s medical records, and each patient will receive a copy of the signed 
document. The use and disclosure of protected health information will be limited to the 
individuals described in the informed consent document.  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 33 of 37 References  
Cho BS, Yahng SA, Lee SE, et al. Validation of recently proposed consensus criteria for  
thrombotic microangiopathy after allogeneic h ematopoietic stem -cell transplantation. 
Transplantation. 2010; 90(8):918 -926. 
 
Choi CM, Schmaier AH, Snell MR, Lazarus HM. Thrombotic microangiopathy in haematopoietic  
stem cell transplantation: diagnosis and treatment. Drugs. 2009; 69(2):183 -198. 
 
Corbac ioglu S, Cesaro S, Faraci M, et al. Defibrotide for prophylaxis of hepatic veno -occlusive  
disease in paediatric haemopoietic stem -cell transplantation: an open -label, phase 3,  
randomised controlled trial. Lancet. 2012; 379(9823):1301 -1309.  
 
Corti P, Uder zo C, Tagliabue A, et al. Defibrotide as a pro mising treatment for thrombotic 
thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow 
Transplant. 2002; 29(6):542 -543 
 
Jodele S, Dandoy CE, Myers KC, et al. New approaches in the diagnosis, pathophysiology, and  
treatment of pediatric hematopoietic stem cell transplantation -associated thrombotic  
microangiopathy. Transfus Apher Sci. 2016; 54(2):[ADDRESS_988057] -associated thrombotic  
microangiopathy: a study in children and young adults. Blood. 2014; 124(4):645 -653. 
 
Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: Diagnosis and management of HSCT - 
associated thrombotic microangiopathy as multi -system endot helial injury. Blood Rev. 2015;  
29(3):191 -204. 
 
Jodele S, Zhang K, Zou F, et al. The genetic fingerprint of susceptibility for transplant  
associated thrombotic microangiopathy. Blood. 2016; 127(8):989 -996. 
 
Kim SS, Patel M, Yum K, Keyzner A. Hematopoietic  stem cell transplant -associated thrombotic  
microangiopathy: review of pharmacologic treatment options. Transfusion. 2015; 55(2):452 -458. 
 
Kojouri K, George JN. Thrombotic microangiopathy following allogeneic hematopoietic stem cell  
transplantation. Curr Opin Oncol. 2007; 19(2):148 -154. 
 
Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and  
beyond: hematopoietic stem cell transplantation -associated thrombotic microangiopathy. Blood.  
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 34 of 37 2011; 118(6):[ADDRESS_988058] -bone marrow transplant thrombotic microangiopathy. Bone  
Marrow Transplant. 2016; 51(7):891 -897. 
 
Richardson PG, Murakami C, Jin Z, et al. Multi -institutional use of defibrotide in 88 patients after  
stem cell transplantation with seve re veno -occlusive disease and multisystem organ failure:  
response without significant toxicity in a high -risk population and factors predictive of outcome.  
Blood. 2002; 100(13):4337 -4343.  
 
Rosenthal J. Hematopoietic cell transplantation -associated thromb otic microangiopathy: a  
review of pathophysiology, diagnosis, and treatment. J Blood Med. 2016; 7:181 -186. 
 
Uderzo C, Bonanomi S, Busca A, et al. Risk factors and severe outcome in thrombotic  
microangiopathy after allogeneic hematopoietic stem cell trans plantation. Transplantation. 2006;  
82(5):[ADDRESS_988059] of thrombotic thrombocytopenic purpura on  
leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant. 2000;  
26(9):[ADDRESS_988060] JR, Majhail NS, Brazauskas R, et al. Long -term survival and late deaths after  
allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230 -2239.  
 
Yeates L, Slatter MA, Bonanomi S, et al. Use of defibrotide to treat transplant -associ ated  
thrombotic microangiopathy: a retrospective study of the Paediatric Diseases and Inborn Errors  
Working Parties of the European Society of Blood and Marrow Transplantation. Bone Marrow  
Transplant. 2017; 52(5):762 -764. 
 
 
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 35 of 37  
11 Appendices  
Appendix 1 Performance Status Criteria  
ECOG Performance Status Scale  Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity  
Fully active, able to carry on all 
pre-disease performance without 
restriction  100 Normal, no com plaints, no evidence 
of disease  
90 Able to carry on normal activity; 
minor signs or symptoms of disease  
1 Symptoms, but ambulatory  
Restricted in physically  strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature ( e.g., light 
housework, office work)  80 Normal activity with effort; some 
signs or sym ptoms of disease  
70 Cares for self, unable to carry on 
norma l activity or  to do active work  
2 In bed <  50% of the time  
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities  
Up and about more than 50% of 
waking hours  [ADDRESS_988061] of his/her 
needs  
50 Requires considerable assis tance 
and frequent medical care  
3 In bed >  50% of the time  
Capable of only limited self -care, 
confined to bed or chair more 
than 50% of waking hours  40 Disabled, requi res special care and 
assistance  
30 Severely disabled , hospi[INVESTIGATOR_723556]  
4 100% bedridden  
Completely disabled  
Cannot carry on any self -care 
Totally confined to bed or chair  20 Very sic k, hospi[INVESTIGATOR_182178]  
10 Moribund, fata l processes 
progressing rapid ly 
5 Dead  0 Dead  
 
 
Version date:  Protocol #:   
Phase II – Study drug(s)   Page 36 of 37 Appendix 2  Prohibited Medications  
Drug  Trade name  (if applicable)  
aspi[INVESTIGATOR_723557] (systemic)  
eculizumab (prophylactic)  
ibuprofen  
naproxen   
Activase  
Soliris  
Advil, Motrin  
Aleve  
  
  
 
 
 
 